Berry SJ, Coffey DS, Walsh PC, et al: The development of human benign prostatic hyperplasia with age. J Urol 132: 474-9, 1984.
Wong SY, Hong A, Leung J, et al: Lower urinary tract symptoms and depressive symptoms in elderly men. J Affect Disord 96: 83-8, 2006.
Rohrmann S, Crespo CJ, Weber JR, et al: Association of cigarette smoking, alcohol consumption and physical activity with lower urinary tract symptoms in older American men: findings from the third National Health And Nutrition Examination Survey. BJU Int 96: 77-82, 2005.
Kupelian V, McVary KT, Kaplan SA, et al: Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey. J Urol 182: 616-24, 2009.
Ohgaki K, Hikima N, Horiuchi K, et al: Association Between Metabolic Syndrome and Male Lower Urinary Tract Symptoms in Japanese Subjects Using Three Sets of Criteria for Metabolic Syndrome and International Prostate Symptom Score. Urology 77: 1432-8, 2011.
Park HK, Lee HW, Lee KS, et al: Relationship between lower urinary tract symptoms and metabolic syndrome in a community-based elderly population. Urology 72: 556-60, 2008.
Temml C, Obermayr R, Marszalek M, et al: Are lower urinary tract symptoms influenced by metabolic syndrome? Urology 73: 544-8, 2009.
Grundy SM, Cleeman JI, Daniels SR, et al: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112: 2735-52, 2005.
AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 170: 530-47, 2003.
Landsberg L: Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med 61: 1081-90, 1986.
Cellek S, Rodrigo J, Lobos E, , et al: Selective nitrergic neurodegeneration in diabetes mellitus—a nitric oxide-dependent phenomenon. Br J Pharmacol 128: 1804-1812, 1999.
Nam SY, Lee EJ, Kim KR, et al: Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. Int J Obes Relat Metab Disord 21: 355-9, 1997.
Mcvary KT, Rademaker A, Lloyd GL, et al: Autonomic nervous system overactivity in men with lower urinary tract symptomssecondary to benign prostatic hyperplasia. J Urol 174: 1327-433, 2005.
Chokkalingam AP, Gao YT, Deng J, et al: Insulin-like growth factors and risk of benign prostatic hyperplasia. Prostate 52: 98-105, 2002.
Devaraj S, Singh U, Jialal I: Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol 20: 182-9, 2009.
Creager MA, Lüscher TF, Cosentino F, et al: Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 108: 1527-32, 2003.
Verma S, Wang CH, Li SH, et al: A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106: 913-9, 2002.
McVary K: Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int 2: 23-8, 2006.
Gao Y, Wang M, Zhang H, et al: Are Metabolic Syndrome and Its Components Associated With Lower Urinary Tract Symptoms? Results from a Chinese Male Population Survey. Urology 2011 Sep 15. [Epub ahead of print]
Eom CS, Park JH, Cho BL, et al: Metabolic syndrome and accompanying hyperinsulinemia have favorable effects on lower urinary tract symptoms in a generally healthy screened population. J Urol 186: 175-9, 2011.)